Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Mar 29, 2024

SELL
$48.26 - $78.59 $126,585 - $206,141
-2,623 Closed
0 $0
Q1 2023

Mar 29, 2024

BUY
$46.97 - $58.27 $62,141 - $77,091
1,323 Added 101.77%
2,623 $127 Million
Q4 2022

Mar 29, 2024

BUY
$52.05 - $65.0 $67,665 - $84,500
1,300 New
1,300 $78.3 Million

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $634M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Kapitalo Investimentos Ltda Portfolio

Follow Kapitalo Investimentos Ltda and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kapitalo Investimentos Ltda, based on Form 13F filings with the SEC.

News

Stay updated on Kapitalo Investimentos Ltda with notifications on news.